EGFR Positive Lung Cancer Latest Advances

EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

Application of puncture tissue rinse solution in the detection of EGFR gene mutations in non-small cell lung cancer

Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Published: June 05, 2026

High-Dose Furmonertinib Management of Advanced NSCLC Harboring an EGFR Exon 14 Missense Mutation: A Case Report and Literature Review.

Journal: The American journal of case reports

Published: June 03, 2026

Correction: The - 216G/T polymorphism in the EGFR gene: a review focusing on non-small cell lung cancer.

Journal: Molecular biology reports

Published: June 03, 2026

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Journal: The New England journal of medicine

Published: May 29, 2026

Explainable 1-mm Peritumoral CT Radiomics for EGFR Mutation Prediction in Non-small Cell Lung Cancer: A Vietnamese Real-World Cohort Study.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: May 26, 2026

Tumor cell-intrinsic NSUN2 deficiency reprograms macrophages to sensitize non-small cell lung cancer to EGFR inhibitors by reversing immune evasion.

Journal: Neoplasia (New York, N.Y.)

Published: April 29, 2026

Leptomeningeal Carcinomatosis During Dose-Reduced Osimertinib Therapy in Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.

Journal: Cureus

Published: April 28, 2026

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

Journal: Cureus

Published: April 17, 2026

Comments on: "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: April 16, 2026

Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 15, 2026

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.

Journal: Nuklearmedizin. Nuclear medicine

Published: April 13, 2026

EGFR Positive Lung Cancer Latest Advances

Find the Latest Research About EGFR Positive Lung Cancer

EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA.

EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA.

Application of puncture tissue rinse solution in the detection of EGFR gene mutations in non-small cell lung cancer

Application of puncture tissue rinse solution in the detection of EGFR gene mutations in non-small cell lung cancer

High-Dose Furmonertinib Management of Advanced NSCLC Harboring an EGFR Exon 14 Missense Mutation: A Case Report and Literature Review.

High-Dose Furmonertinib Management of Advanced NSCLC Harboring an EGFR Exon 14 Missense Mutation: A Case Report and Literature Review.

Correction: The - 216G/T polymorphism in the EGFR gene: a review focusing on non-small cell lung cancer.

Correction: The - 216G/T polymorphism in the EGFR gene: a review focusing on non-small cell lung cancer.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Explainable 1-mm Peritumoral CT Radiomics for EGFR Mutation Prediction in Non-small Cell Lung Cancer: A Vietnamese Real-World Cohort Study.

Explainable 1-mm Peritumoral CT Radiomics for EGFR Mutation Prediction in Non-small Cell Lung Cancer: A Vietnamese Real-World Cohort Study.

Tumor cell-intrinsic NSUN2 deficiency reprograms macrophages to sensitize non-small cell lung cancer to EGFR inhibitors by reversing immune evasion.

Tumor cell-intrinsic NSUN2 deficiency reprograms macrophages to sensitize non-small cell lung cancer to EGFR inhibitors by reversing immune evasion.

Leptomeningeal Carcinomatosis During Dose-Reduced Osimertinib Therapy in Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.

Leptomeningeal Carcinomatosis During Dose-Reduced Osimertinib Therapy in Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

Comments on: "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy".

Comments on: "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy".

Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.

Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.